zonisamide has been researched along with Baltic Myoclonic Epilepsy in 4 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Action myoclonus frequently remains the primary cause of disability in Unverricht-Lundborg disease (EPM1) patients." | 1.37 | A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. ( Bramanti, P; Coppola, A; Ferlazzo, E; Italiano, D; Magaudda, A; Pezzella, M; Striano, P; Striano, S; Zara, F, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 1 |
| Kälviäinen, R | 1 |
| Genton, P | 1 |
| Andermann, E | 1 |
| Andermann, F | 1 |
| Magaudda, A | 2 |
| Frucht, SJ | 1 |
| Schlit, AF | 1 |
| Gerard, D | 1 |
| de la Loge, C | 1 |
| von Rosenstiel, P | 1 |
| Italiano, D | 1 |
| Pezzella, M | 1 |
| Coppola, A | 1 |
| Ferlazzo, E | 1 |
| Bramanti, P | 1 |
| Striano, S | 1 |
| Zara, F | 1 |
| Striano, P | 1 |
| Kagitani-Shimono, K | 1 |
| Imai, K | 1 |
| Okamoto, N | 1 |
| Ono, J | 1 |
| Okada, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht[NCT00357669] | Phase 3 | 50 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht[NCT00368251] | Phase 3 | 56 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 17.45 |
| Brivaracetam 5 mg/Day | -4.60 |
| Brivaracetam 150 mg/Day | 12.34 |
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 0.00 |
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -9.68 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 5.41 |
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 43.44 |
| Brivaracetam 150 mg/Day | 0.00 |
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement). (NCT00368251)
Timeframe: End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Brivaracetam 150 mg/Day | 11.1 | 11.1 | 33.3 | 33.3 | 5.6 | 5.6 | 0 |
| Brivaracetam 5 mg/Day | 10.0 | 0 | 30.0 | 50.0 | 10.0 | 0 | 0 |
| Placebo | 0 | 11.1 | 33.3 | 50.0 | 0 | 0 | 5.6 |
1 trial available for zonisamide and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
3 other studies available for zonisamide and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
A pilot open-label trial of zonisamide in Unverricht-Lundborg disease.
Topics: Adult; Aged; Anticonvulsants; Female; Humans; Isoxazoles; Male; Middle Aged; Myoclonus; Pilot Projec | 2011 |
Unverricht-Lundborg disease with cystatin B gene abnormalities.
Topics: Adolescent; Alleles; Anticonvulsants; Blotting, Southern; Cystatin B; Cystatins; DNA Mutational Anal | 2002 |